To explore the expression of DPP4 in patients with neuropathic pain

注册号:

Registration number:

ITMCTR1900002381

最近更新日期:

Date of Last Refreshed on:

2019-06-05

注册时间:

Date of Registration:

2019-06-05

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

探究DPP4在神经病理性疼痛中的表达

Public title:

To explore the expression of DPP4 in patients with neuropathic pain

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探究DPP4在神经病理性疼痛中的表达

Scientific title:

To explore the expression of DPP4 in patients with neuropathic pain

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900023655 ; ChiMCTR1900002381

申请注册联系人:

边疆

研究负责人:

边疆

Applicant:

Jiang Bian

Study leader:

Jiang Bian

申请注册联系人电话:

Applicant telephone:

+86 18096308622

研究负责人电话:

Study leader's telephone:

+86 18096308622

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1105593984@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1105593984@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国四川省泸州市龙马潭区春晖路182号

研究负责人通讯地址:

中国四川省泸州市龙马潭区春晖路182号

Applicant address:

182 Chunhui Road, Longmatan District, Luzhou, Sichuan, China

Study leader's address:

182 Chunhui Road, Longmatan District, Luzhou, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西南医科大学附属中医医院

Applicant's institution:

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

西南医科大学附属中医医院

Primary sponsor:

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University

研究实施负责(组长)单位地址:

中国四川省泸州市龙马潭区春晖路182号

Primary sponsor's address:

182 Chunhui Road, Longmatan District, Luzhou, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

泸州

Country:

China

Province:

Sichuan

City:

Luzhou

单位(医院):

西南医科大学附属中医医院

具体地址:

龙马潭区春晖路16号

Institution
hospital:

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University

Address:

182 Chunhui Road, Longmatan District

经费或物资来源:

课题经费资助

Source(s) of funding:

Project funding

研究疾病:

神经病理性疼痛

研究疾病代码:

Target disease:

Neuropathic pain

Target disease code:

研究类型:

Study type:

基础科学研究

Basic Science

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

探究DPP4在神经病理性疼痛中的表达。

Objectives of Study:

To explore the expression of DPP4 in neuropathic pain.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合神经病理性疼痛的诊断标准者; (2)年龄在18-75岁之间、入院前未接受阿片类药物治疗; (3)自愿参加试验研究,并已签署知情同意书者。

Inclusion criteria

(1) patients who meet the diagnostic criteria for neuropathic pain. (2) aged 18 to 75 years, not receiving opioid treatment before admission. (3) voluntarily participate in the study and have signed the informed consent.

排除标准:

(1)已知对存在药物过敏者。 (2)无法合作者,如合并有神经、精神疾患等或不愿合作者。 (3)有酒精、药物滥用史者。 (4)正在参加或试验前12周内参加过其他临床试验者。 (5)合并有严重内、外科疾病。 (6)严重精神病史或长期使用精神活性物质。

Exclusion criteria:

(1) people who are known to have drug allergies. (2) unable to cooperate, such as combined with neurological disorders, mental disorders, etc., or unwilling to cooperate. (3) having a history of alcohol or drug abuse. (4) participants who have participated in other clinical trials within 12 weeks prior to or before the trial. (5) complicated with serious internal and surgical diseases. (6) history of severe mental illness or long-term use of psychoactive substances.

研究实施时间:

Study execute time:

From 2019-06-05

To      2019-06-05

征募观察对象时间:

Recruiting time:

From 2019-06-05

To      2019-06-05

干预措施:

Interventions:

组别:

神经病理性疼痛患者组+正常对照组

样本量:

120

Group:

patients with neuropathic pain group + healthy control group

Sample size:

干预措施:

干预措施代码:

none

Intervention:

none

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川省

市(区县):

泸州市

Country:

China

Province:

Sichuan

City:

Luzhou

单位(医院):

西南医科大学附属中医医院

单位级别:

三甲医院

Institution/hospital:

Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

二肽基肽酶4

指标类型:

主要指标

Outcome:

DPP4

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

β-内啡肽

指标类型:

主要指标

Outcome:

β-EP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

γ-干扰素

指标类型:

主要指标

Outcome:

IFN-γ

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素17

指标类型:

主要指标

Outcome:

IL-17

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素-1β

指标类型:

主要指标

Outcome:

IL-1β

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在中国试验注册中心公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

made public at the Chinese clinical trial registry

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

建立研究对象档案,电子档案管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Establish research object file, electronic file management

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above